Kybernin P (Antithrombin Iii)

Antithrombin III is a natural inhibitor of several serine proteases in the coagulation cascade, most notably thrombin and factor Xa. By binding to these enzymes, it accelerates their inactivation, thereby reducing fibrin formation and limiting clot development. The administered concentrate replenishes plasma antithrombin, restoring normal anticoagulant control.

The dose of Kybernin P is individualized by the prescribing clinician based on the patient’s antithrombin activity, body weight, clinical condition, and the therapeutic goal. Laboratory monitoring of antithrombin levels guides dose adjustments, and the prescriber sets the exact regimen.

Safety data for Kybernin P in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians must weigh the potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To order Kybernin P, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.

Kybernin P is a purified antithrombin III concentrate delivered as an intravenous solution, similar in function to other licensed antithrombin products. Compared with plasma‑derived formulations, it offers a standardized antithrombin content and reduced risk of viral transmission, while providing rapid plasma level correction. Choice of product depends on local availability, regulatory status and clinician preference.

Kybernin P must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to administration, inspect the solution for particulate matter or discoloration and use within the recommended time after removal from refrigeration.

Kybernin P is administered intravenously by slow infusion under the supervision of a qualified healthcare professional. The infusion rate and total volume are determined by the prescriber based on the target antithrombin activity and patient-specific factors. Monitoring of antithrombin levels and clinical response is performed during and after the infusion.

Serious risks include anaphylaxis, which can be life‑threatening and requires immediate treatment, and paradoxical thrombotic events despite anticoagulation. Rarely, hemolysis and renal impairment have been reported. Prompt recognition of these events and appropriate medical intervention are essential.

Kybernin P should be avoided in patients with known hypersensitivity to antithrombin III or any component of the formulation. Caution is also advised for individuals with uncontrolled bleeding, severe renal dysfunction without dose adjustment, or those in whom the risk of thrombosis outweighs the benefit of antithrombin supplementation.